Cure
Overview
The latest women’s health venture capital news, updated monthly—tracking funding rounds of $3M or more across fertility & reproductive health, menopause & midlife, maternal health, oncology & diagnostics, endometriosis & hormonal conditions, and more.
For more, explore our Biotech Funding and Medtech Funding trackers, updated weekly.
July 2026
The American Baby Company
Date: July 23, 2026 Series: Seed Amount: $4M Therapeutic area: Fertility & reproductive health Modality: Care delivery / fertility clinic Investors: Wormhole Capital and Tower Research Ventures
The American Baby Company raised $4M to open its first clinic in West Palm Beach, Florida, this fall. Founded by Van Spina and reproductive endocrinologist Dr. Paul Magarelli, the company prices IVF at $8,995 and egg freezing at $4,995 with medications included, using stronger upfront diagnostics and protocol-driven care to cut costs.
Juno Bio
Date: July 16, 2026 Series: Seed Amount: $3.8M Therapeutic area: Endometriosis & hormonal conditions Modality: Diagnostics Investors: Led by Ada Ventures; with Artesian, Entrepreneur First, and Illumina Accelerator
Juno Bio raised $3.8M and opened the first CLIA-certified sequencing lab dedicated entirely to women's health, in Oakland, California. The platform scales precision vaginal microbiome testing and STI screening, giving clinicians actionable insight into infections, fertility, and menopausal health.
SONATA
Date: July 14, 2026 Series: Seed Amount: $7M Therapeutic area: Other therapeutics Modality: Preventive care membership / diagnostics Investors: Led by Lux Capital; with BoxGroup, Sunflower Capital, and angels including the founders of Ramp and Linear
SONATA launched a physician-led preventive health membership across New York, San Francisco, and Los Angeles with $7M in backing. The $2,500 annual membership combines whole-genome sequencing, more than 140 blood biomarkers, DNA methylation analysis, and wearable data with unlimited physician access and clinical AI built in-house.
Corner Health
Date: July 9, 2026 Series: Seed and Series A Amount: $32.5M Therapeutic area: Other therapeutics Modality: Care delivery / AI-enabled provider network Investors: Series A led by Oak HC/FT; with existing investors First Round Capital and Zigg Capital
Corner Health announced $32.5M in seed and Series A financing to help nurse practitioners start and scale their own primary care practices. The network spans more than 70 provider-owned practices across Arizona and Washington and enabled over 35,000 patient visits in the past year. The company positions the model as particularly relevant for women, who use healthcare services at higher rates than men.
Notable M&A and Partnerships
Wildflower Health acquires Every Mother
Date: July 21, 2026 Deal type: Acquisition Amount: Undisclosed Therapeutic area: Maternal health Modality: Digital care platform
Wildflower Health acquired Every Mother, a digital pelvic floor and core rehabilitation platform, adding programs across pregnancy, postpartum recovery, surgical recovery, and perimenopause. The deal marks Wildflower's first move into direct-to-consumer care.
GoRocky acquires Kindred Health
Date: July 21, 2026 Deal type: Acquisition Amount: Undisclosed Therapeutic area: Other therapeutics Modality: Telehealth / hybrid clinic
Philippines-based telehealth platform GoRocky acquired Kindred Health, a hybrid women's health provider offering consultations, diagnostics, ultrasounds, and care spanning infertility, menopause, and infectious disease through a virtual platform and a flagship clinic in Bonifacio Global City. More than 60% of GoRocky's weight management patients are women.
ONTO Health acquires LEVY Health
Date: July 7, 2026 Deal type: Acquisition Amount: Undisclosed Therapeutic area: Fertility & reproductive health Modality: Clinical decision support software
ONTO Health acquired LEVY Health, a clinical decision support company providing precision diagnostics and patient intake for reproductive medicine. Funded by ONTO's recent Series A, the deal supports expansion across the U.S. and into the Gulf Cooperation Council region.
Genentech and Astex Pharmaceuticals
Date: July 6, 2026 Deal type: Research collaboration and license agreement Amount: Up to $490M ($25M upfront, plus milestones and royalties) Therapeutic area: Oncology & diagnostics Modality: Small-molecule therapeutics
Astex entered an exclusive worldwide collaboration and license agreement with Genentech, a member of the Roche Group, to identify small-molecule candidates for breast cancer. Genentech takes sole responsibility for preclinical and clinical development and global commercialization. The program originated in Astex's alliance with Newcastle University and Cancer Research Horizons.
June 2026
Materna Medical
Date: June 30, 2026 Series: Series B3 Amount: $5M Therapeutic area: Maternal health Modality: Medical device Investors: InnovaHealth Partners, Wavemaker360 Health, and Band of Angels, with continued support from existing investors
Materna Medical closed a $5M B3 financing to advance its Ellora Obstetrical System, an investigational device designed to reduce pelvic floor muscle injury during vaginal delivery in first-time mothers. The funding supports the readout of its EASE pivotal trial, expanded channel access for Milli, its FDA-cleared vaginal dilator, and commercial manufacturing buildout. A first-in-class reimbursement code for the device is now active.
Clair Health
Date: June 17, 2026 Series: Seed Amount: $11.6M Therapeutic area: Hormonal conditions Modality: Wearable / continuous monitoring Investors: Led by Khosla Ventures; with a16z speedrun, Brydge Club, Treehub, Cartan Capital, Insiders VC, and Anne Wojcicki
Clair Health, founded by two recent Stanford grads, raised $11.6M to build the first noninvasive, continuous hormone monitor for women, tracking estrogen, progesterone, LH, and FSH without blood draws. A consumer launch is planned for late 2026.
Rejoni
Date: June 16, 2026 Series: Growth Amount: $25M Therapeutic area: Fertility & reproductive health Modality: Medical device Investors: ClavystBio, Amed Ventures, Ascension Ventures, Catalyst Health Ventures, Delos Capital, FemHealth Ventures, Iyengar Capital, and Sparta Group
Rejoni secured $25M in financing to accelerate its Juveena Hydrogel System toward FDA approval and commercial launch. The catheter-delivered device places a temporary hydrogel spacer in the uterine cavity to support endometrial healing and reduce intrauterine adhesions following intrauterine surgery.
Mammogen
Date: June 10, 2026 Series: Series A Amount: Up to $30M Therapeutic area: Oncology & diagnostics Modality: Blood test / diagnostic Investors: Led by a major U.S. public retirement system
Mammogen raised up to $30M to advance its RNA-powered blood test for earlier breast cancer detection and to reduce unnecessary biopsies.
Contraline
Date: June 2, 2026 Series: Series B Amount: $92.5M Therapeutic area: Fertility & reproductive health Modality: Hormonal drug (gel) Notable Investors: Co-led by BVF Partners and RA Capital Management; with GV, Lumira Ventures, and Invus
Charlottesville, Virginia–based Contraline raised $92.5M to advance NES/T, an investigational once-daily, reversible hormonal male contraceptive gel, into late-stage (Phase 3) development. The funds support its lead program and additional pipeline assets.
May 2026
Oli (Baymatob)
Date: May 26, 2026 Series: Series A3 Amount: $6.5M Therapeutic area: Maternal health Modality: Wearable device Investors: Scale Investors, Clare Ventures, and the University of Sydney
Australia-based Baymatob raised $6.5M to advance Oli, its wireless wearable for predictive maternal and fetal monitoring during labor, ahead of market entry. Oli has raised over $13M in private capital and over $9M in non-dilutive funding to date.
UroMems
Date: May 15, 2026 Series: Series D Amount: $60M Therapeutic area: Other therapeutics Modality: Implantable device Investors: Led by Ajax Health Fund I
French-American UroMems raised $60M, its largest round to date, to advance its smart, automated artificial urinary sphincter implant for stress urinary incontinence, a condition that disproportionately affects women.
April 2026
ScreenPoint Medical
Date: April 17, 2026 Series: Growth (existing investors) Amount: $16M ($14M equity + $2M non-dilutive grants) Therapeutic area: Oncology & diagnostics Modality: AI diagnostic software Investors: Insight Partners and Siemens Healthineers
Nijmegen, Netherlands–based ScreenPoint raised $16M to scale its Transpara breast-cancer detection AI, now deployed in 30+ countries with over 12 million mammograms processed.
Osteoboost Health
Date: April 15, 2026 Series: Seed Amount: $8M Therapeutic area: Menopause & midlife Modality: Wearable device Investors: Led by Ambit Health Ventures; with Emmeline Ventures, Disrupt Health Impact Fund, Esplanade Ventures, and Portfolia
Osteoboost Health raised $8M to scale its FDA-cleared wearable that treats low bone density in postmenopausal women with osteopenia through targeted vibration therapy.
ONTO Health
Date: April 15, 2026 Series: Series A Amount: $20M Therapeutic area: Fertility & reproductive health Modality: Digital health / AI care Investors: ARTIS and Humania
ONTO Health, led by reproductive endocrinologist Dr. Roohi Jeelani, raised $20M to expand its AI-enabled fertility and longevity care platform across the U.S. and into the Gulf Cooperation Council region. The platform combines evidence-based fertility care with AI diagnostics and clinical automation.
Wavelet Medical
Date: April 14, 2026 Series: Seed Amount: $7M Therapeutic area: Maternal health Modality: AI monitoring device Investors: Led by Aegis Ventures
Wavelet Medical raised $7M to bring the first non-invasive, AI-powered fetal brain (EEG) monitoring to labor and delivery, detecting fetal brain distress in real time.
Flora Fertility
Date: April 7, 2026 Series: Seed Amount: $5M Therapeutic area: Fertility & reproductive health Modality: Insurance / fintech Investors: Led by ManchesterStory; with Slauson & Co. and BDC
Flora Fertility raised $5M for individually owned fertility insurance that isn't tied to employment.
SimpliFed
Date: April 7, 2026 Series: Series A Amount: $10.8M Therapeutic area: Maternal health Modality: Digital health / virtual care Investors: Co-led by Morningside and Hesperia Capital; with Foreground Capital, AHA Social Impact Fund, and Elizabeth Street Ventures
SimpliFed, founded by Andrea Ippolito, raised $10.8M to expand from virtual lactation support into full virtual OB care, serving patients from pregnancy through postpartum in partnership with health systems and clinics.
March 2026
Nadia Care
Date: March 16, 2026 Series: Growth Amount: $12M Therapeutic area: Maternal health Modality: Care delivery / virtual + community Investors: Led by Valtruis and a national payer; with First Trust Capital Partners and RH Capital
Nadia Care (formerly Cayaba Care) raised $12M to expand its community-centered maternal care model across the U.S. Its model has produced a 60% reduction in NICU days and 38% lower preterm birth rates among members served through regional Medicaid plans.
May Health
Date: March 10, 2026 Series: Growth (existing + new investors) Amount: $11.7M Therapeutic area: Fertility & reproductive health Modality: Medical device Investors: Sofinnova Partners, Trill Impact, Bpifrance, and new investor Nexpring Health
May Health raised $11.7M to advance its Anavi System, a device for PCOS-related infertility, through its U.S. pivotal IDE trial (REBALANCE) and to support European launch planning.
February 2026
Sensei Biotherapeutics / Faeth Therapeutics
Date: February 18, 2026 Series: Acquisition + $200M private placement Amount: ~$200M Therapeutic area: Oncology & diagnostics Modality: Oral therapeutic (M&A) Investors: Private placement co-led by RA Capital Management, Vivo Capital, Cormorant Asset Management, and Fairmount
Sensei Biotherapeutics acquired Faeth Therapeutics alongside a $200M private placement, advancing Faeth's PIKTOR, an oral therapy targeting the PI3K/AKT/mTOR pathway for endometrial and breast cancer.
Midi Health
Date: February 3, 2026 Series: Series D Amount: $100M (at $1B+ valuation) Therapeutic area: Menopause & midlife Modality: Digital health / virtual care Investors: Led by Goodwater Capital; with Foresite Capital, Serena Ventures, Advance Venture Partners, GV, Emerson Collective, SemperVirens, and McKesson Ventures
Midi Health raised $100M, crossing a $1B valuation, to scale its virtual perimenopause and menopause platform across all 50 states, adding OB-GYN, cardiology, and dermatology services.
January 2026
Pee Safe
Date: January 2026 Series: Series C Amount: $32M Therapeutic area: Other therapeutics Modality: Consumer health Investors: Led by OrbiMed; with Alkemi Growth Capital
Pee Safe raised $32M to scale its period, feminine, and intimate-hygiene and personal-care business, expanding into 23 international markets.
Science&Humans
Date: January 2026 Series: Series A Amount: $7M Therapeutic area: Endometriosis & hormonal conditions Modality: Digital health / telehealth platform Investors: Led by Pender Ventures; with WELL Health Technologies, CIBC Innovation Banking, and Michele Romanow
Toronto-based Science&Humans raised $7M to scale its hormone-health platform across Canada, treating PCOS, PMS, PMDD, endometriosis, perimenopause, and menopause.
ShanX Medtech
Date: January 14, 2026 Series: Seed Amount: $28M Therapeutic area: Oncology & diagnostics Modality: Diagnostic device Investors: Borski Fund, NextGen Ventures, CbusineZ, BOM, and Invest-NL
Netherlands-based ShanX Medtech raised $28M for its ultra-rapid antimicrobial susceptibility testing platform, initially focused on UTIs, which disproportionately affect women.
Feminai
Date: January 12, 2026 Series: Seed Amount: $6M Therapeutic area: Oncology & diagnostics Modality: Wearable / AI Investors: Led by Vertex Ventures Israel; with ICI Fund, Fusion VC, Arben Ventures, and Cactus Capital
Israel-based Feminai raised $6M to develop its AI-powered wearable for at-home breast cancer screening.
BrightHeart
Date: January 8, 2026 Series: Series A Amount: $12.6M Therapeutic area: Maternal health (prenatal diagnostics) Modality: AI diagnostic software Investors: Co-led by Odyssée Venture and GO Capital; with Sofinnova Partners and the Mussallem CHD Alliance
BrightHeart (France/U.S.) raised over $12M to scale its FDA-cleared AI platform for prenatal ultrasound, which improves congenital heart defect detection to over 96%. Funds support U.S. commercialization and European expansion.
Pomelo Care
Date: January 8, 2026 Series: Series C Amount: $92M (at $1.7B valuation) Therapeutic area: Maternal health Modality: Digital health / virtual care Investors: Led by Stripes; with Andreessen Horowitz, PLUS Capital, Atomico, BoxGroup, and SV Angel
Pomelo Care raised $92M to grow its virtual maternity model into broader women's and children's health, including reproductive care, pediatrics, and menopause. The company now covers more than 25 million lives.
